Leiden, the Netherlands, February 7, 2025: On December 15, 2024, Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., announced a recommended cash offer to the ...

The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The Netherlands, ...

Leiden, the Netherlands, June 24, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it will host a webcast for investors and analysts featuring ...

The average one-year price target for Pharming Group N.V. - Depositary Receipt (NasdaqGM:PHAR) has been revised to $19.77 / share. This is an increase of 11.55% from the prior estimate of $17.73 dated ...

CSL Behring and Pharming have mutually agreed that CSL will dismiss Pharming from the case against Dr. Chiao Pharming's dismissal did not involve any fault, liability, or penalties against Pharming ...

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Pharming (NASDAQ:PHAR) in the last three months. The following table provides a quick overview ...

At the end of June, Pharming reported that 114 patients in the U.S. aged 12 and older were on paid therapy, generating $23 million in Joenja revenues in the first half of 2025. RBC Capital Markets ...

This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to ...

When we look around, we are amazed at the speed with which the world is changing. Online fraud techniques such as Pharming and other cybercrime attacks are at an all-time high. To overcome such ...

Leiden, The Netherlands, October 13, 2008. Biotech companyPharmingGroup NV ("Pharming" or "The Company") (Euronext: PHARM)announcedtoday the appointment of Dr Sijmen de Vries as ChiefExecutiveOfficer ...